Etirinotecan pegolEtirinotecan pegol (trade name Onzeald) is a drug developed by Nektar Therapeutics for the treatment of certain kinds of breast cancer with brain metastases. The European Medicines Agency refused to grant it a marketing authorisation in 2017. Read from the Drugbox of the Wikipedia article Etirinotecan pegol, revision 1341543034.

Property

Value

Formula

C161H192N20O40, 3047.40 g/mol

Elimination half-life

912 h

The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.